Toxicity and survival associated with IV/IP chemotherapy following neoadjuvant chemotherapy and interval debulking surgery for epithelial ovarian, fallopian tube, and primary peritoneal cancer

被引：0
|
作者：
Rios-Doria, E. [1 ]
Pezzillo, M. [1 ]
Ulm, M. A. [2 ]
Tillmanns, T. [2 ]
机构：
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[2] Univ Tennessee, West Canc Ctr, Memphis, TN USA
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷
关键词：
D O I：
10.1016/j.ygyno.2020.05.157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269
引用
收藏
页码：127 / 128
页数：2
相关论文
共 50 条
  • [31] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    Alexandre A. B. A. da Costa
    Camila V. Valadares
    Glauco Baiocchi
    Henrique Mantoan
    Augusto Saito
    Solange Sanches
    Andréia P. Guimarães
    Maria Isabel W. Achatz
    Annals of Surgical Oncology, 2015, 22 : 971 - 978
  • [32] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    da Costa, Alexandre A. B. A.
    Valadares, Camila V.
    Baiocchi, Glauco
    Mantoan, Henrique
    Saito, Augusto
    Sanches, Solange
    Guimaraes, Andreia P.
    Achatz, Maria Isabel W.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S971 - S978
  • [33] Benefits of neoadjuvant chemotherapy in ovarian, primary peritoneal, or fallopian tube carcinoma.
    Brown, Alaina J.
    Huang, Marilyn
    Sun, Charlotte C.
    Zaid, Tarrik M.
    Balakrishnan, Nyla
    Mhadgut, Hemendra
    Lu, Karen H.
    Westin, Shannon Neville
    Bodurka, Diane C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: Comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 176
  • [35] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Ce Bian
    Kui Yao
    Li Li
    Tao Yi
    Xia Zhao
    Archives of Gynecology and Obstetrics, 2016, 293 : 163 - 168
  • [36] Postoperative survival analysis of laparotomy versus robotic interval debulking in epithelial ovarian cancer patients following neoadjuvant chemotherapy
    Paraghamian, S. E.
    Staley, A.
    Tucker, K.
    Zhang, Y.
    Wang, M.
    Clark, L. H.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 148 - 148
  • [37] Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
    Liu, Ying L.
    Filippova, Olga T.
    Zhou, Qin
    Iasonos, Alexia
    Chi, Dennis S.
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger J.
    Broach, Vance A.
    O'Cearbhaill, Roisin E.
    Konner, Jason A.
    Aghajanian, Carol
    Roche, Kara Long
    Tew, William P.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (01)
  • [38] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Bian, Ce
    Yao, Kui
    Li, Li
    Yi, Tao
    Zhao, Xia
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 293 (01) : 163 - 168
  • [39] Cost-effectiveness of hyperthermic intraperitoneal chemotherapy HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy
    Lim, Stephanie L.
    Havrilesky, Laura J.
    Habib, Ashraf S.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2019, 153 (02) : 376 - 380
  • [40] COST-EFFECTIVENESS OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) AT INTERVAL DEBULKING OF EPITHELIAL OVARIAN CANCER FOLLOWING NEOADJUVANT CHEMOTHERAPY
    Lim, S.
    Havrilesky, L.
    Cohn, D.
    Habib, A.
    Secord, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 627 - 627
12345